A Phase I Safety and Pharmacokinetic/Pharmacodynamic Study of CP-724, 714 In Patients With Metastatic HER2-Overexpressing Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 03 Aug 2012
At a glance
- Drugs CP 724714 (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 17 Jun 2011 Actual end date (May 2005) added as reported by ClinicalTrials.gov.
- 21 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.